Gastroenterology & AI

Research and developments at the intersection of artificial intelligence and healthcare.

Why it matters: AI is transforming how we diagnose, treat, and prevent disease. Staying informed helps clinicians and patients make better decisions.

11 research items

Get updates on this topic

Sort by Date Sort by Relevance

Drug Watch

Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial

From: 2026-05-29

Nature Medicine - AI Section⭐Promising2 min read

New drug targets rare, drug-resistant stomach cancer

Key Takeaway:

A phase 2 trial shows the drug rogaratinib targets a specific genetic pathway to successfully treat a rare, drug-resistant form of gastrointestinal stomach cancer.

A multicenter phase 2 clinical trial evaluated a new drug called rogaratinib for patients with a rare subtype of gastrointestinal stromal tumor. This specific cancer is notoriously difficult to treat because it resists the standard drugs used for other stomach tumors. Rogaratinib works by blocking a specific cellular pathway to stop the cancer from growing. The trial results showed encouraging clinical effectiveness, proving that targeting this specific genetic pathway can successfully treat this stubborn form of cancer and offering patients a much-needed new treatment option.

What this means for you

This early-stage study shows a new drug, rogaratinib, may help treat a rare stomach cancer. It is not yet widely available, and patients should not change their current treatment plans.

Oncology Clinical Trial Gastroenterology

Citation:

Nature Medicine - AI Section, 2026. DOI: s41591-026-04376-9 Read article →

Drug Watch

From: 2026-05-28

Nature Medicine - AI Section⭐Promising2 min read

New drug targets rare, drug-resistant stomach tumors

Key Takeaway:

A new phase 2 trial shows that the drug rogaratinib successfully targets a genetic switch to treat rare, drug-resistant gastrointestinal tumors.

A clinical trial published in Nature Medicine evaluated a drug called rogaratinib for patients with a specific, hard-to-treat subtype of gastrointestinal stromal tumors. These tumors lack a key enzyme, making them resistant to standard cancer drugs. Rogaratinib works by blocking a different cellular pathway, bypassing the tumor's natural resistance. The trial demonstrated encouraging clinical success, proving that targeting this alternative genetic switch is an effective way to treat patients who previously had very few therapeutic options.

What this means for you

This early-stage study shows a new drug, rogaratinib, may help treat a rare type of stomach tumor. It is not yet widely available, and patients should not change their current treatments.

Oncology Clinical Trial Gastroenterology Precision Medicine

Citation:

Nature Medicine - AI Section, 2026. DOI: s41591-026-04376-9 Read article →

Safety Alert

From: 2026-02-27

ArXiv - Quantitative BiologyExploratory3 min read

New genetic element accelerates antibiotic resistance spread

Key Takeaway:

Researchers discovered a new genetic element, Tn7722, that significantly spreads antibiotic resistance in Klebsiella pneumoniae, posing a growing threat to global health.

Researchers studying Klebsiella pneumoniae, a bacterium responsible for severe hospital-acquired infections, have discovered a new genetic vehicle named Tn7722. This element carries a gene that makes the bacteria resistant to carbapenems, which are critical, last-resort antibiotics. The discovery explains how this dangerous resistance is spreading rapidly, posing a major challenge to global healthcare systems.

What this means for you

This early research highlights a new way antibiotic resistance spreads in bacteria. It's not yet ready for clinical use. Continue following your doctor's advice and don't change your care based on this study.

Drug Discovery Observational Study Breakthrough Gastroenterology

Citation:

ArXiv, 2026. arXiv: 2603.01849 Read article →

Safety Alert

Tomorrow’s Smart Pills Will Deliver Drugs and Take Biopsies

From: 2026-02-23

IEEE Spectrum - BiomedicalExploratory3 min read

Smart pills will deliver medicine and take gut biopsies

Key Takeaway:

Researchers are developing smart pills that can deliver drugs and take tissue samples in the gut, potentially reducing the need for invasive procedures in the future.

Going through an endoscopy or a colonoscopy to check for digestive issues can be highly uncomfortable and invasive. To solve this, researchers are developing high-tech smart pills designed to make gastrointestinal diagnostics completely painless. These electronic capsules are smaller than a standard multivitamin and can easily travel through the digestive tract. As they move, they assess tissue health, detect signs of cancer, and transmit diagnostic data back to doctors. Remarkably, these smart pills are also being designed with the dual capability to deliver targeted medication directly to diseased tissue and even perform micro-biopsies on the go.

What this means for you

Exciting early research on smart pills may reduce invasive procedures in the future. However, it's not available yet. Continue following your doctor's current recommendations and discuss any concerns with them.

Drug Discovery Gastroenterology

Citation:

IEEE Spectrum - Biomedical, 2026. Read article →

Extracorporeal liver cross-circulation using transgenic xenogeneic pig livers with brain-dead human decedents

From: 2026-02-11

Nature Medicine - AI Section⭐Exploratory3 min read

Transgenic pig livers offer bridge to human transplant

Key Takeaway:

Genetically modified pig livers can temporarily support liver function in brain-dead patients, offering a potential bridge to transplantation in the future.

In a study published in Nature Medicine, researchers connected genetically modified pig livers to four brain-dead human decedents. The pig livers were engineered to prevent immediate immune rejection by the human body. During the study, the external pig livers successfully performed vital hepatic functions, showing that this method could temporarily support patients suffering from acute liver failure until a human transplant becomes available.

What this means for you

This is early research using pig livers for temporary support. It’s not available yet and may take years. Please continue with your current care and consult your doctor for any concerns.

Gastroenterology Clinical Decision Breakthrough

Citation:

Nature Medicine - AI Section, 2026. DOI: s41591-025-04196-3 Read article →

From: 2026-02-09

Nature Medicine - AI Section⭐Exploratory3 min read

Modified pig livers temporarily support human circulation

Key Takeaway:

Genetically modified pig livers can temporarily support liver function in brain-dead humans, potentially serving as a bridge to transplantation in the future.

In a groundbreaking experiment, researchers connected genetically modified pig livers to four brain-dead human bodies using an external tubing system. The pig livers were specifically engineered to prevent rejection by the human immune system. Over a 72-hour period, the animal organs successfully performed essential human liver functions, such as filtering blood. This study shows that the technique is functional and safe for short-term use, offering hope that modified animal organs could one day serve as a temporary bridge to keep critically ill patients alive while they wait for a human donor organ.

What this means for you

This is very early research. It may take years before this technique is available. Please continue with your current care plan and discuss any questions with your doctor.

Gastroenterology Clinical Trial Breakthrough

Citation:

Nature Medicine - AI Section, 2026. DOI: s41591-025-04196-3 Read article →

From: 2026-01-07

Nature Medicine - AI Section⭐Exploratory3 min read

Obesity care must include liver risk screening

Key Takeaway:

Clinicians should include liver risk assessments when managing obesity, as metabolic-associated steatotic liver disease (MASLD) is increasingly common and linked to obesity.

A study of 2,500 individuals with obesity highlights the urgent need to screen for metabolic-associated steatotic liver disease during routine obesity care. Researchers used specialized imaging and biological markers to evaluate liver scarring, fat buildup, and inflammation. The findings show that liver complications are highly prevalent in obese patients, meaning doctors should actively screen and categorize liver risk to prevent severe, irreversible organ damage.

What this means for you

"Early research highlights obesity's link to liver disease. It's not ready for clinical use yet. Continue following your doctor's advice and discuss any concerns about liver health during your appointments."

Gastroenterology Diagnostic AI Clinical Trial

Citation:

Nature Medicine - AI Section, 2026. DOI: s41591-025-04130-7 Read article →

Multi-omic definition of metabolic obesity through adipose tissue–microbiome interactions

From: 2025-12-31

Nature Medicine - AI Section⭐Exploratory3 min read

Gut bacteria interactions define metabolic obesity

Key Takeaway:

New research reveals how interactions between fat tissue and gut bacteria contribute to metabolic obesity, offering insights for better diagnosis and treatment of this condition.

A study analyzed data from five hundred participants to understand metabolic obesity, a condition where individuals of normal body weight still suffer from obesity-related metabolic dysfunction. By combining genetic, protein, and gut microbiome data, researchers mapped how fat tissue interacts with gut bacteria. They discovered specific microbial signatures and chemical pathways that correlate with unhealthy fat tissue. This deeper biological understanding could lead to better diagnostic tools and targeted therapies to treat metabolic issues before they cause severe health problems.

What this means for you

This early research on metabolic obesity is promising but not yet ready for clinical use. Continue following your doctor's advice and don't change your care based on this study.

Gastroenterology Observational Study Radiology Breakthrough

Citation:

Nature Medicine - AI Section, 2026. DOI: s41591-025-04009-7 Read article →

Devices Target the Gut to Maintain Weight Loss from GLP-1 Drugs

From: 2025-12-31

IEEE Spectrum - BiomedicalExploratory3 min read

Endoscopic devices sustain GLP-1 weight loss

Key Takeaway:

Endoscopic devices may help maintain weight loss achieved with GLP-1 drugs, offering a promising new tool for long-term obesity management.

While GLP-1 receptor agonist drugs are highly effective for weight loss, many patients struggle with regaining weight once they stop taking the medication. Researchers are investigating the use of endoscopic medical devices that target the gastrointestinal tract to help maintain weight loss. These minimally invasive devices are designed to alter gut mechanics or signaling. The study suggests that combining temporary drug therapy with these gut-targeting devices could offer patients a sustainable, long-term solution for managing obesity without requiring lifelong medication.

What this means for you

This research is promising but still in early stages. It may take years before it's available. Continue following your current treatment plan and discuss any questions with your doctor.

Gastroenterology Clinical Decision

Citation:

IEEE Spectrum - Biomedical, 2026. Read article →

From: 2025-12-29

IEEE Spectrum - BiomedicalExploratory3 min read

Endoscopic gut devices help maintain GLP-1 weight loss

Key Takeaway:

New endoscopic devices may help maintain weight loss achieved with GLP-1 drugs, offering a promising strategy for long-term obesity management.

Popular GLP-1 receptor agonist medications are highly effective at helping people lose weight, but patients frequently regain the weight once they stop taking the drugs. To solve this problem, biomedical engineers are testing specialized endoscopic devices that are temporarily placed inside the gastrointestinal tract. These devices physically alter how the gut senses food, mimicking the natural fullness signals triggered by the medications. Early research suggests that using these minimally invasive devices after a patient finishes their drug regimen can successfully prevent weight regain, offering a long-term strategy for obesity management.

What this means for you

This is early research, not yet available for use. It may take years before it's an option. Continue following your current treatment plan and discuss any questions with your doctor.

Gastroenterology Clinical Decision

Citation:

IEEE Spectrum - Biomedical, 2026. Read article →

Is It Time To Equip Our Toilets With Health Sensors?

From: 2025-12-19

The Medical FuturistExploratory3 min read

Smart toilets could monitor your health daily

Key Takeaway:

Integrating health sensors into toilets could soon allow for daily, non-invasive health monitoring by analyzing waste, potentially aiding early detection of various conditions.

The best way to treat a disease is to catch it early, but most people only visit the doctor when they already feel sick. Researchers are proposing a simple solution: putting health sensors inside everyday toilets. By automatically analyzing urine and stool, these smart toilets can look for hidden biomarkers like glucose, proteins, and blood. This continuous, hands-free monitoring could alert users to early signs of diabetes, kidney issues, or gut diseases. This technology would allow people to seek medical help early, preventing minor issues from turning into major emergencies.

What this means for you

"Exciting early research suggests toilets could monitor health, but it's years away. Don't change your care yet. Keep following your doctor's advice and stay informed about new developments."

Clinical Decision Gastroenterology

Citation:

The Medical Futurist, 2025. Read article →

Exploring Gastroenterology? Learn how to interpret medical AI research →